Grifols, S.A. (NASDAQ:GRFS) Receives $10.58 Consensus Price

Shares of Grifols, S.A. (NASDAQ:GRFS – Get Free Report) have earned an average rating of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 […]

Related Keywords

Spain , United States , Canada , Vistaseal Veraseal , Albutein Flexbag , Grifols Company Profile , Goldman Sachs Group Inc , Wells Fargo Company , Orion Portfolio Solutions , Get Free Report , Marketbeat Ratings , Portfolio Solutions , Goldman Sachs Group , Sachs Group , Get Free , Gamunexc Immune Globulin Injection , Flebogamma Immune Globulin Intravenous , Xembify Immune Globulin Subcutaneous , Immune Globulin , Lynspad Alpha , Proteinase Inhibitor , Human Albumin , Plasbumin Albumin , Grifols Daily , Grifols , Nasdaq Grfs , Grfs , Medical , Ratings , Consensus ,